Key facts
- This page summarizes Scott Tarriff's Form 4 filing for EAGLE PHARMACEUTICALS, INC. (EGRX).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 01 Mar 2024, 16:40.
Scott Tarriff - 28 Feb 2024 Form 4 Insider Report for EAGLE PHARMACEUTICALS, INC. (EGRX)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- EGRX
- Reported as of
- 28 Feb 2024
- Net transaction value
- -$13,286
- SEC form
- 4
- Accepted by SEC
- 01 Mar 2024, 16:40:02 UTC
- Prior SEC filing
- 29 Feb 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Scott Tarriff
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Scott Tarriff filed Form 4 for EAGLE PHARMACEUTICALS, INC. (EGRX) on 01 Mar 2024.
Change
- Previous filing in this sequence was filed on 29 Feb 2024.
- Current net transaction value: -$13,286.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
EGRX
transaction
Common Stock
Tax liability
- Transaction value
- $13,286
- Shares
- -2,119
- Change %
- -0.46%
- Price
- $6.27
- Shares after
- 460,621
- Date
- 28 Feb 2024
- Ownership
- Direct
- Footnotes
- F1
EGRX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 992,623
- Date
- 28 Feb 2024
- Ownership
- By Tarriff 2016 Generation Skipping Exempt Family Trust DTD 12/28/2016
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units on February 28, 2024.
Footnote F2
Shares held by the Tarriff 2016 Generation Skipping Exempt Family Trust DTD 12/28/2016 (the "Trust") for the benefit of the Reporting Person's spouse and children. The Reporting Person does not have investment control over the shares held by the Trust and disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest, if any, therein.